DNA-PK Inhibitor IV MF: C11H13NO3
MW: 207.23
A potent, selective, ATP-competitive DNA-PK inhibitor.

DNA-PK Inhibitor IV

DNA-PK Inhibitor IV is rated 5.0 out of 5 by 1.
  • y_2020, m_11, d_22, h_16
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.12
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_221562, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 141ms
  • REVIEWS, PRODUCT
5
1
4
0
3
0
2
0
1
0
Alternate Names: 2-Hydroxy-4-morpholin-4-yl-benzaldehyde
Application: DNA-PK Inhibitor IV is a potent, selective, ATP-competitive DNA-PK inhibitor
Molecular Weight: 207.23
Molecular Formula: C11H13NO3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data (including water content).

DNA-PK Inhibitor IV morpholino-salicylaldehyde acts as a potent, selective and ATP-competitive inhibitor of DNA-PK. It inhibits PI 3-K catalytic subunit p110-isozymes at higher concentrations and weakly inhibits a panel of several other kinases. DNA-PK Inhibitor IV is an inhibitor of PI 3-kinase p110 α, PI 3-kinase p110 β and PI 3-kinase p110 δ.


References

1. Kashishian, Adam., et al., 2003. DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer. Molecular cancer therapeutics. 2(12): 1257-64. PMID: 14707266
2. Willmore, Elaine., et al., 2004. A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. Blood. 103(12): 4659-65. PMID: 15010369
3. Knight, Zachary A., et al., 2004. Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorganic & medicinal chemistry. 12(17): 4749-59. PMID: 15358300

Physical State :
Solid
Solubility :
Soluble in DMSO (5 mg/ml).
Storage :
Store at -20° C
Melting Point :
126.99° C (Predicted)
Boiling Point :
401.3° C at 760 mmHg (Predicted)
Density :
1.27 g/cm3 (Predicted)
Refractive Index :
n20D 1.61 (Predicted)
IC50 :
DNA-PK: IC50 = 0.43 µM; PI 3-kinase p110 α: IC50 = 10 µM; PI 3-kinase p110 β: IC50 = 2.8 µM; PI 3-kinase p110 γ: IC50 = 37 µM; PI 3-kinase p110 δ: IC50 = 5.1 µM
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
PubChem CID :
9815659
MDL Number :
MFCD00228054
SMILES :
C1COCCN1C2=CC(=C(C=C2)C=O)O

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 122ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Imamichi Imamichi, S. et al. (PubMed 25391321) used DNA-PK Inhibitor IV to report that ionizing radiation-induced XRCC4 phosphorylation is mediated through ATM in addition to DNA-PK. -SCBT Publication Review
Date published: 2015-02-01
  • y_2020, m_11, d_22, h_16
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.12
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_221562, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 7ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.